Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.
about
Functional Implications of the Binding Mode of a Human Conformation-Dependent V2 Monoclonal Antibody against HIVThe V1V2 Region of HIV-1 gp120 Forms a Five-Stranded Beta Barrel.HIV-1 vaccines: challenges and new perspectivesPentavalent HIV-1 vaccine protects against simian-human immunodeficiency virus challenge.Nonneutralizing functional antibodies: a new "old" paradigm for HIV vaccinesSequence-conserved and antibody-accessible sites in the V1V2 domain of HIV-1 gp120 envelope protein.Partial rescue of V1V2 mutant infectivity by HIV-1 cell-cell transmission supports the domain's exceptional capacity for sequence variation.Rationally Designed Vaccines Targeting the V2 Region of HIV-1 gp120 Induce a Focused, Cross-Clade-Reactive, Biologically Functional Antibody Response.Vaccine-induced Human Antibodies Specific for the Third Variable Region of HIV-1 gp120 Impose Immune Pressure on Infecting VirusesAntibody light-chain-restricted recognition of the site of immune pressure in the RV144 HIV-1 vaccine trial is phylogenetically conserved.Estimated secondary structure propensities within V1/V2 region of HIV gp120 are an important global antibody neutralization sensitivity determinant.Rationally Targeted Mutations at the V1V2 Domain of the HIV-1 Envelope to Augment Virus Neutralization by Anti-V1V2 Monoclonal Antibodies.Identification of New Regions in HIV-1 gp120 Variable 2 and 3 Loops that Bind to α4β7 Integrin Receptor.Comparable Antigenicity and Immunogenicity of Oligomeric Forms of a Novel, Acute HIV-1 Subtype C gp145 Envelope for Use in Preclinical and Clinical Vaccine ResearchHuman Antibodies that Recognize Novel Immunodominant Quaternary Epitopes on the HIV-1 Env Protein.Conserved Role of an N-Linked Glycan on the Surface Antigen of Human Immunodeficiency Virus Type 1 Modulating Virus Sensitivity to Broadly Neutralizing Antibodies against the Receptor and Coreceptor Binding SitesAdenoviral vectors elicit humoral immunity against variable loop 2 of clade C HIV-1 gp120 via "Antigen Capsid-Incorporation" strategy.Rationally Designed Immunogens Targeting HIV-1 gp120 V1V2 Induce Distinct Conformation-Specific Antibody Responses in Rabbits.The HIV-1 gp120 V1V2 loop: structure, function and importance for vaccine development.Monoclonal Antibodies Specific for the V2, V3, CD4-Binding Site, and gp41 of HIV-1 Mediate Phagocytosis in a Dose-Dependent MannerPlasticity and Epitope Exposure of the HIV-1 Envelope Trimer.Distinct mechanisms regulate exposure of neutralizing epitopes in the V2 and V3 loops of HIV-1 envelope.Extracellular Matrix Proteins Mediate HIV-1 gp120 Interactions with α4β7.Particulate Array of Well-Ordered HIV Clade C Env Trimers Elicits Neutralizing Antibodies that Display a Unique V2 Cap Approach.Non-neutralizing Antibodies Targeting the V1V2 Domain of HIV Exhibit Strong Antibody-Dependent Cell-mediated Cytotoxic Activity.Functional Antibody Response Against V1V2 and V3 of HIV gp120 in the VAX003 and VAX004 Vaccine Trials.Reduced cell-associated DNA and improved viral control in macaques following passive transfer of a single anti-V2 monoclonal antibody and repeated SHIV challenges.Generation and characterization of a bivalent protein boost for future clinical trials: HIV-1 subtypes CR01_AE and B gp120 antigens with a potent adjuvant.Common helical V1V2 conformations of HIV-1 Envelope expose the α4β7 binding site on intact virions
P2860
Q27681527-91909F08-30CC-4DDF-8E72-429523745A14Q30152923-6059D4B2-A366-476E-B7DF-5AA85CEC8C23Q33577972-40543EF8-4FF5-4BB9-ADEF-110BCE44C1DFQ33804531-FC81F560-18CE-4BA0-927E-5AA1162282DFQ34057711-304DD13D-B5FB-44BC-873E-A93C2B972292Q34116932-6D84E1EB-7473-4185-9EE7-2FCF9AB540EBQ34309493-5DCE91FC-5DDC-4A86-AE04-A3A7D7E85E55Q34540352-0E5D1A04-A743-448E-8276-30BC3829FCF4Q34948847-08F1F852-B467-463A-BC3D-AE0645E70170Q35073270-498435CC-E321-41B1-8F33-675C1AFB8892Q35140508-471D7689-E538-4089-8819-DD433C5FEB41Q35817106-33FF824C-28A3-4803-BA6B-70281D00A0ACQ35857404-85825371-C424-4474-B9C1-26CE9E7CF3BBQ35861256-0447E063-E629-45B5-9D15-9A1EE1F63F9AQ36076117-E463728A-813D-49DE-85BE-D6D537988A5DQ36434294-269A66A3-CE21-41BE-B0EB-812D17B073DDQ36625165-136EB053-6A77-4BC7-B3E1-DD58E3A36212Q37448281-1123BB9B-0DA3-4DBB-ADCD-6D036EF58718Q38243948-5181592D-A549-4317-B65E-B8838B683F83Q38719420-37B42D28-5337-414C-A73E-421D195B2181Q38725480-70EAD4BB-111F-433D-B379-F21D2552741DQ38962226-3C7C59D4-6353-4EE5-8D86-A9DE370048DEQ40080908-29937708-0297-4020-B32F-7896FBC49EF0Q40198048-611952B8-226F-4B12-AC27-3A9B8498814CQ41924059-D16B1AA9-7D73-403B-B2A1-CDB6EB3B8FA3Q47555452-A5AD91AD-BBD9-4CE4-87D2-FE77F3B75811Q51743315-FEE5D068-FDEF-4B16-8283-F815B70F1C9FQ52561260-A6753A9C-C11C-4C69-8B9C-DEB8E0D878D1Q58115616-8B9EEA4D-C104-4485-8F41-88A77CACF09E
P2860
Epitope mapping of conformational V2-specific anti-HIV human monoclonal antibodies reveals an immunodominant site in V2.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Epitope mapping of conformatio ...... an immunodominant site in V2.
@ast
Epitope mapping of conformatio ...... an immunodominant site in V2.
@en
Epitope mapping of conformatio ...... an immunodominant site in V2.
@nl
type
label
Epitope mapping of conformatio ...... an immunodominant site in V2.
@ast
Epitope mapping of conformatio ...... an immunodominant site in V2.
@en
Epitope mapping of conformatio ...... an immunodominant site in V2.
@nl
prefLabel
Epitope mapping of conformatio ...... an immunodominant site in V2.
@ast
Epitope mapping of conformatio ...... an immunodominant site in V2.
@en
Epitope mapping of conformatio ...... an immunodominant site in V2.
@nl
P2093
P2860
P1433
P1476
Epitope mapping of conformatio ...... an immunodominant site in V2.
@en
P2093
Brett Spurrier
Luzia M Mayr
Sandra Cohen
Susan Zolla-Pazner
Xiang-Peng Kong
P2860
P304
P356
10.1371/JOURNAL.PONE.0070859
P407
P577
2013-07-29T00:00:00Z